Platelet Rich Plasma- Platelet Concentrate Therapy in COPD: An Observational Cohort Study
Journal Title: Journal of Regenerative Medicine & Biology Research - Year 2021, Vol 2, Issue 2
Abstract
Objective: Current management of Chronic Obstructive Pulmonary Disease (COPD) is aimed at improving symptoms and preventing exacerbations, yet those treatments cannot alter the natural progression of lung function decline over time. Autologous cellular therapy with PRPPC may help prevent decline and improve quality of life among these patients. Methods: 419 participants with COPD enrolled in this study underwent autologous cellular therapy with PRP-PC and outcomes measures assessed over the course of a year. Lung function with spirometry and breathing-related quality of life was assessed on all patients at baseline. Quality of life was re-assessed on all participants after 3, 6 and 12 months by phone and 150 participants returned for repeat spirometry after 3 months. Safety monitoring was done on all participants during the study. Results: Participants with COPD, undergoing autologous cellular therapy with PRP-PC, had a statistically significant increase in FEV1% predicted at 3 months post-treatment. In addition, they had a statistically and clinically significant increase in subjective quality of life at 3-, 6- months and 12 months post-treatment. Adverse events were rare and minor and largely related to the process of drawing blood. Conclusion: Advanced treatments such as autologous cellular therapy with PRP-PC can be a safe, effective option for helping to mitigate the natural progression of COPD. This study and others published in the literature have found significant improvements in pulmonary function and quality of life when autologous PRP-PC is used. Current pharmacologic therapies are aimed at relieving symptoms and preventing acute exacerbations, but cellular therapy may alter the progressive decline of chronic lung disease over time. Cellular therapies should be considered as a safe, valuable, potential therapy for these patients. An additional comparative, randomized, double blind study comparing this PRP-PC protocol plus standard of care versus standard of care alone is being planned.
Authors and Affiliations
Melissa M Rubio
Keywords
Related Articles
- EP ID EP698854
- DOI http://dx.doi.org/10.46889/JRMBR.2021.2201
- Views 82
- Downloads 0
Informed Consent Guidelines for Optimizing the Use of Telomerase-Positive Stem Cells
The objectives of the work, based on previous characterization studies, pre-clinical animal models of induced diseases, e.g., Parkinson disease, cardiovascular disease, pulmonary disease, and type-I diabetes mellitus,...
The Jounced Entrails-Intestine in COVID-19
Coronavirus disease 2019 (COVID-19), initiated by contemporary coronavirus is a pandemic which engenders severe respiratory disease. SARS-CoV-2 preponderantly transmits through airborne particles and mammoth respirator...
Numerous Types of Stem Cells Possess Potential to Treat Congenital Hydrocephalus
Twenty-five percent of premature neonate’s experience Intraventricular Hemorrhage (IVH) and 10% of these events are complicated further by the occurrence of hydrocephalus. The number of infants at high risk for IVH and t...
Expression of Neuron Specific Neuronal Nuclei Protein (NeuNNP) by AAV2 Shows Diagnosis Ability in Spinal Cord Injury Using Neural Stem Cells
Fibroblast Growth Factor (FGF) shows promising therapy for Spinal Cord Injury (SCI). Neural stem transplantation has been on the role implementing tactics to repair SCI. Considering the hostile hypoxia condition in SCI...
3D Bioprinting for Tissue Engineering Amidst the Century Cataclysm
The coronavirus is one of our modernistic day’s major universal, human defies. The human brain is planned to prefer the present-day and underrate the future. That triggers it hard to prohibit disasters like pandemics. Nu...